Pharmalot… Pharmalittle… Evening Edition
2 CommentsBy Ed Silverman // July 10th, 2007 // 6:57 pm
And so we returned from a brief sojourn to still more interesting developments, and a bit of a heat wave here in the nation’s medicine chest. Is life hot where you are? If so, while you’re sipping that cold drink, please enjoy these…
Can Caution Be Too Risky? (Reason)
House Votes On PDUFA Bill On Wednesday (Congressional Quarterly)*
McKesson’s Promising Prognosis (BusinessWeek)
Moody’s Weighs Ratings As Patents Expires (Yahoo/Reuters)
Japan Plans To Double Use Of Generics (The Daily Yomiuri)
Depomed Shares Plunge As Drug Fails (Bloomberg News)
Authorized Generics Trip Up India’s Big Players (The Business Standard)
New Diabetes Meds Work No Better Than Older Ones (Bloomberg News)
* subscription may be required
jason
Ed, thanks for publishing the too risky article. That really supports my thought that there is no way to quickly approve only the meds that have no possibility of being harmful. The big debate still raging on the ped AD posts is proof that there is much controversy on this subject. I consider the articles in those journals to carry a lot of weight. The size of the studies in the quality of journals cannot be written off as “these are drug company lackeys”. There is certainly still a debate, but all information is good. I notice this isn’t grabbing the national headlines like the first round talking about how SSRI’s are killing our kids got. You won’t see this leading the nightly news, or mentioned at all.
Ed Silverman
Hi Jason,
I like finding different kinds of things, even if some contradict other pieces. It should all, hopefully, encourage discussion and provide more opportunity for folks to learn. So I agree with you that all, or more, info is good.
As for risk itself, well, my experience is that its relative. One man’s risk is another man’s benefit, and vice versa. My sense is this debate will be with us a long time, until the pendulum veers toward the middle ground.
Time to catch some sleep.
ed